Our study indicated that EGFRvIII expression could decrease the sensitivity of breast cancer cells against trastuzumab via activating the ERK, AKT and Jak1/STAT3 pathways (Figure 1), which suggested that EGFRvIII inhibitor might reduce trastuzumab resistance. Here, AKT1 is linked to breast carcinoma.